Yes, a subamendment.
I also want to note that this process has been made very difficult by having the committee meet today instead of Monday—or maybe we're meeting Monday as well—and having the amendments basically go in at noon yesterday. We've been scrambling. As we go through them today, I hope you will be accommodating just because it's been a lot of stuff to get in order in less than 24 hours. So I just want to make that note.
In terms of our friendly amendment, what we would like to do is to add a paragraph (d). Mr. Young has got paragraphs (a), (b) and (c). We would like to add a paragraph (d) and the subamendment would be:
For greater clarity, confidential business information does not include safety and efficacy information including phase 1 to phase 3 pre-market trials or post-market safety assessments, clinical study reports and periodic safety update reports.
So we just want to make it clear that confidential business information doesn't include those things that I've just listed. That's just for greater clarity. We support the amendment but think that the subamendment would bring greater clarity.